An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline

Schoffski Patrick; Elisei Rossella; Mueller Stefan; Brose Marcia S; Shah Manisha H; Licitra Lisa F; Jarzab Barbara; Medvedev Viktor; Kreissl Michael; Niederle Bruno; Cohen Ezra E W; Wirth Lori J; Ali Haythem Y; Hessel Colin; Yaron Yifah; Ball Douglas Wilmot; Nelkin Barry; Sherman Steven I; Schlumberger Martin

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline

作者：Schoffski Patrick; Elisei Rossella; Mueller Stefan; Brose Marcia S; Shah Manisha H; Licitra Lisa F; Jarzab Barbara; Medvedev Viktor; Kreissl Michael; Niederle Bruno; Cohen Ezra E W; Wirth Lori J; Ali Haythem Y; Hessel Colin; Yaron Yifah; Ball Douglas Wilmot; Nelkin Barry; Sherman Steven I; Schlumberger Martin

来源：48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 2012-06-01 to 2012-06-06.

出版日期2012-5-20

收藏分享被引(32) 浏览

更新时间：2018-04-10 22:36

相似论文
引用论文
参考文献

An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline

产品服务

站内浏览

服务支持

联系方式

科研之友